Overview

Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The goal of the present study is to test if in situations of borderline resectable patients a neoadjuvant treatment combining Gemzar-Abraxane and stereotactic radiosurgery could increase the median OS rates above 30 months that means at least 12 months more than the 18-20 months generally described.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Francois Baclesse, Luxembourg